BioCentury | Feb 4, 2010
Cover Story

Revoking serotonin's auto license

Although the majority of marketed antidepressants are designed to boost low levels of the neurotransmitter serotonin in the brain-a well-known cause of depression-only a third of patients actually respond to the first drug they are...
BioCentury | Jun 5, 2008
Distillery Therapeutics

This Week in Therapeutics

...seen in untreated controls. Next steps could involve clinical trials of IL-12 to treat MM. Expression Genetics Inc.'s...
BioCentury | Mar 24, 2008
Emerging Company Profile

Bacilligen: Building on bacteria

Bacilligen Inc. . has three bacteria-based technology platforms that it believes confer safety, efficacy and manufacturing advantages when developing vaccines and therapeutics for infectious diseases and cancer, as well as allowing rapid manufacturing of therapeutic proteins...
BioCentury | Jul 30, 2007
Clinical News

EGEN-001: Phase I started

...in up to 30 patients with recurrent epithelial ovarian cancer to evaluate EGEN-001 plus chemotherapy. Expression Genetics Inc....
BioCentury | May 7, 2007
Company News

Expression Genetics, U.S. Food and Drug Administration cancer news

...The interleukin-12 (IL-12) gene expression plasmid and biocompatible delivery polymer is in Phase I testing. Expression Genetics Inc....
BioCentury | Apr 23, 2007
Clinical News

EGEN-001: Phase I data

...for 4 weeks. The compound was safe and well tolerated. EGEN-001 has Orphan Drug designation. Expression Genetics Inc....
BioCentury | Oct 24, 2005
Clinical News

EGEN-001: Phase I started

...up to 18 patients. EGEN-001 has Orphan Drug designation in the U.S. for this indication. Expression Genetics Inc....
Items per page:
1 - 7 of 7
BioCentury | Feb 4, 2010
Cover Story

Revoking serotonin's auto license

Although the majority of marketed antidepressants are designed to boost low levels of the neurotransmitter serotonin in the brain-a well-known cause of depression-only a third of patients actually respond to the first drug they are...
BioCentury | Jun 5, 2008
Distillery Therapeutics

This Week in Therapeutics

...seen in untreated controls. Next steps could involve clinical trials of IL-12 to treat MM. Expression Genetics Inc.'s...
BioCentury | Mar 24, 2008
Emerging Company Profile

Bacilligen: Building on bacteria

Bacilligen Inc. . has three bacteria-based technology platforms that it believes confer safety, efficacy and manufacturing advantages when developing vaccines and therapeutics for infectious diseases and cancer, as well as allowing rapid manufacturing of therapeutic proteins...
BioCentury | Jul 30, 2007
Clinical News

EGEN-001: Phase I started

...in up to 30 patients with recurrent epithelial ovarian cancer to evaluate EGEN-001 plus chemotherapy. Expression Genetics Inc....
BioCentury | May 7, 2007
Company News

Expression Genetics, U.S. Food and Drug Administration cancer news

...The interleukin-12 (IL-12) gene expression plasmid and biocompatible delivery polymer is in Phase I testing. Expression Genetics Inc....
BioCentury | Apr 23, 2007
Clinical News

EGEN-001: Phase I data

...for 4 weeks. The compound was safe and well tolerated. EGEN-001 has Orphan Drug designation. Expression Genetics Inc....
BioCentury | Oct 24, 2005
Clinical News

EGEN-001: Phase I started

...up to 18 patients. EGEN-001 has Orphan Drug designation in the U.S. for this indication. Expression Genetics Inc....
Items per page:
1 - 7 of 7